Centrul National Clinic De Recuperare Neuropsihomotorie Copii Dr. Nicolae Robanescu
- Address
- lock Available on a paid plan
Congenital, Hereditary, and Neonatal Diseases
The pediatric neurology unit is conducting research on rare genetic conditions, aiming to improve therapeutic options and quality of life for affected children.
- Evaluation of novel agents for Prader‑Willi syndrome
- Safety monitoring of long‑term treatments in early‑onset disorders
- Genetic counseling impact on disease management
These studies are carried out at Centrul National Clinic De Recuperare Neuropsihomotorie Copii Dr. Nicolae Robanescu in Bucharest, providing families with access to cutting‑edge care.
Musculoskeletal Diseases
Clinical investigations focus on muscular degeneration, seeking to enhance motor function and delay disease progression in young patients.
- Dose comparison of emerging therapy for Duchenne muscular dystrophy
- Assessment of functional outcomes in ambulant children
- Exploration of exon‑skipping strategies
The site’s multidisciplinary team collaborates with genetic laboratories to tailor interventions for each child’s specific mutation profile.
Nervous System Diseases
Research in this area targets seizure disorders, evaluating new medications for efficacy and tolerability in pediatric populations.
- Efficacy of brivaracetam in childhood and juvenile absence epilepsy
- Comparative study of clemizole HCl for Lennox‑Gastaut syndrome
- Long‑term safety monitoring of antiepileptic therapies
By enrolling children from 2 to 25 years old, the trials aim to reduce seizure frequency and improve daily functioning.
Genetic Phenomena
The facility explores how genetic mechanisms influence disease expression, supporting the development of precision medicines.
- Investigation of genetic biomarkers for treatment response
- Studies on exon‑skipping efficacy in muscular dystrophy
- Impact of gene‑based diagnostics on therapeutic planning
These projects complement the clinical trials, fostering a deeper understanding of inherited conditions treated at the clinic.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Epygenix Therapeutics Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1UCB Biopharma3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrul National Clinic De Recuperare Neuropsihomotorie Copii Dr. Nicolae Robanescu
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-Label, Follow-Up Study to Assess the Long-Term Use of Oral Lacosamide in Study Participants Who Completed EP0034 or SP848 and Received Lacosamide Treatment | UCB Biopharma | Phase III | Not Recruiting | Dec 2020 | Feb 2025 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Brivaracetam | 2 | Unknown | 2022-03-10 | 2024-11-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.